Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AC2592 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AC2592 | DRUG | continuous subcutaneous infusion (via pump), dose based on subject body weight |
| placebo | DRUG | continuous subcutaneous infusion (via pump), dose based on subject body weight |
Main Inclusion Criteria: * Has heart failure classified as New York Heart Association (NYHA) Class III or Class IV at screening despite treatment with standard therapy. * Is able to perform a treadmill test. * Has an HbA1c of \<= 11%. * Is physically and mentally capable of operating the continuous...
AC2592 is an investigational small molecule being developed for the treatment of congestive heart failure. It is intended for patients with advanced chronic congestive heart failure, a condition in which the heart cannot pump blood effectively. The drug is administered by continuous subcutaneous infusion and is currently in clinical development.
AC2592 is being developed by AstraZeneca PLC, a multinational pharmaceutical company. AstraZeneca is listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of AC2592 for the treatment of congestive heart failure.
AC2592 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 2 trial for AC2592 has been completed, and the drug is not yet available for commercial use.
AC2592 has been studied in one clinical trial with the identifier NCT00099580. This Phase 2 trial, titled 'PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure,' was a randomized, double-blind, placebo-controlled study conducted in the United States. The trial enrolled 61 participants and has been completed.
AC2592 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed Phase 2 trial evaluated its effects in patients with advanced chronic congestive heart failure, but the drug has not yet received regulatory approval and is not available for prescription.
AC2592 is administered by continuous subcutaneous infusion, meaning it is delivered under the skin over an extended period. This method of administration was used in the Phase 2 clinical trial for patients with advanced chronic congestive heart failure. The drug is a small molecule, and its administration method is designed for chronic treatment.